Trial Profile

A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of JADE101 in Participants With Immunoglobulin A Nephropathy (JUNIPER)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 23 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JADE 101 (Primary)
Indications IgA nephropathy
Focus Adverse reactions
Acronyms JUNIPER
Sponsors Jade Biosciences

Most Recent Events

07 May 2026 According to Jade Bioscience media release, company expects to begin this study is second quarter of 2026 and interim data in 2027. Also, a Trial-in-Progress presentation will be delivered during an oral session at the 2026 ERA Congress.
23 Apr 2026 Status changed from planning to not yet recruiting.
18 Mar 2026 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com